Vitamin K Treatment Reduces Undercarboxylated Osteocalcin but Does Not Alter Bone Turnover, Density, or Geometry in Healthy Postmenopausal North American Women
Vitamin K Treatment Reduces Undercarboxylated Osteocalcin but Does Not Alter Bone Turnover, Density, or Geometry in Healthy Postmenopausal North American Women
复制标题
DOI：
10.1359/jbmr.081254
复制
发表时间：
2009-06-01
影响因子：
6.2
通讯作者：
Suttie, John
中科院分区：
文献类型：
--
作者：
Binkley, Neil;Harke, Judith;Suttie, John
维生素K水平低与骨密度低和骨折风险增加有关。此外，一种特殊的美萘醌，美萘醌（MK4），可能会降低骨折风险。然而，维生素K是否对北美女性的骨骼健康起作用仍不清楚。此外，各种维生素K（如叶绿醌和MK4）可能对骨骼有不同的影响。本研究的目的是评估叶绿醌或MK4治疗对非骨质疏松、绝经后北美妇女骨骼转换和骨密度标志物的影响。在这项双盲、安慰剂对照研究中，38.1名绝经后妇女接受叶绿醌（每天1毫克）、MK4（每天45毫克）或安慰剂治疗12个月。所有参与者每天补充钙和维生素D-3。血清骨特异性碱性磷酸酶（BSALP）和I型胶原蛋白n端肽（NTX）在基线、1、3、6和12个月时测量。腰椎和股骨近端骨密度和股骨近端几何形状在基线、6和12个月时用DXA测量。在基线时，三个治疗组在人口统计学或研究终点上没有差异。钙、叶绿醌和MK4治疗的依从性分别为93%、93%和87%。叶绿醌和MK4治疗降低了血清羧化骨钙素，但没有改变BSALP或NTX。叶绿醌或MK4对腰椎、股骨近端骨密度或股骨近端几何参数均无影响。这项研究不支持补充维生素K在健康、绝经后、接受钙和维生素D补充的北美妇女预防骨质疏松症中的作用。[J]中华骨科学杂志，2009;24(2):983-991。2008年12月29日在线发布；doi: 10.1359 / JBMR.081254
Low vitamin K status is associated with low BMD and increased fracture risk. Additionally, a specific menaquinone, menatetrenone (MK4), may reduce fracture risk. However, whether vitamin K plays a role in the skeletal health of North American women remains unclear. Moreover, various K vitamers (e.g-, phylloquinone and MK4) may have differing skeletal effects. The objective of this study was to evaluate the impact of phylloquinone or MK4 treatment on markers of skeletal turnover and BMD in nonosteoporotic, postmenopausal, North American women. In this double-blind, placebo-controlled study, 38.1 postmenopausal women received phylloquinone (1 mg daily), MK4 (45 mg daily), or placebo for 12 mo. All participants received daily calcium and vitamin D-3 supplementation. Serum bone-specific alkaline phosphatase (BSALP) and n-telopeptide of type I collagen (NTX) were measured at baseline and 1, 3, 6, and 12 mo. Lumbar spine and proximal femur BMD and proximal femur geometry were measured by DXA at baseline and 6 and 12 mo. At baseline, the three treatment groups did not differ in demographics or study endpoints. Compliance with calcium, phylloquinone, and MK4 treatment was 93%, 93%, and 87%, respectively. Phylloquinone and MK4 treatment reduced serum undercarboxylated osteocalcin but did not alter BSALP or NTX. No effect of phylloquinone or MK4 on lumbar spine or proximal femur BMD or proximal femur geometric parameters was observed. This study does not support a role for vitamin K supplementation in osteoporosis prevention among healthy, postmenopausal, North American women receiving calcium and vitamin D supplementation. J Bone Miner Res 2009;24:983-991. Published online on December 29, 2008; doi: 10.1359/JBMR.081254